You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 華大基因漲逾6% 全資子公司與沙特NUPCO籤2.65億美元產品買賣和服務協議
格隆匯 04-27 10:35
格隆匯4月27日丨華大基因(300676.SZ)漲逾6%,報112.5元,總市值450億元。華大基因今早公佈,2020年4月26日,公司的全資子公司BGI HEALTH (HK) CO., LTD(中文名“華大基因健康科技(香港)有限公司”,下稱“香港醫學”)與沙特阿拉伯王國的National Unified Procurement Company(NUPCO)在中國香港簽訂了《產品買賣和服務協議》。香港醫學為NUPCO提供新冠病毒檢測綜合解決方案,包含檢測儀器和設備、檢測試劑盒及檢測實驗室設計方案等。合同總金額不超過約2.65億美元,合同期限為自合同生效之日起的八個月,經雙方協商一致,合同期限可以延長三個月或更短時間。公司表示,隨着新冠疫情的全球性蔓延擴散,公司憑藉自身傳感染防控領域深厚的經驗積累,研製生產的新冠病毒檢測試劑盒產品陸續取得國內醫療器械註冊證、歐盟CE認證、美國FDA簽發的EUA(緊急使用授權)、日本PMDA認證和澳大利亞TGA註冊。此次公司與NUPCO的合作,旨在助力沙特當地的新冠疫情防控工作。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account